{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:47:16Z","timestamp":1791384436347,"version":"4.3.3"},"reference-count":53,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Ivabradine is a recently introduced inhibitor of the If ion channel, which exhibits the capacity to reduce heart rate while preserving hemodynamic stability. At present, ivabradine finds its clinical indication in patients suffering from heart failure with reduced ejection fraction and maintaining a relative sinus rhythm refractory to beta-blockers. To optimize heart rate control, it is recommended to pursue an aggressive up-titration of ivabradine. This approach may ameliorate tachycardia-induced hypotension by incrementally enhancing cardiac output and allow further up-titration of agents aimed at ameliorating heart failure, such as beta-blockers. Both the modulation of heart rate itself and the up-titration of agents targeting heart failure lead to cardiac reverse remodeling, consequently culminating in a subsequent reduction in mortality and morbidity. A novel overlap theory that our team proposed recently has emerged in recent times. Under trans-mitral Doppler echocardiography, the E-wave and A-wave closely juxtapose one another without any overlapping at the optimal heart rate. Employing echocardiography-guided ivabradine for heart-rate modulation to minimize the overlap between the E-wave and A-wave appears to confer substantial benefits to patients with heart failure. This approach facilitates superior cardiac reverse remodeling and yields more favorable clinical outcomes when compared to those patients who do not receive echocardiography-guided care. The next pertinent issue revolves around the potential expansion of ivabradine\u2019s clinical indications to encompass a broader spectrum of diseases. It is imperative to acknowledge that ivabradine may not yield clinically significant benefits in patients afflicted by heart failure with preserved ejection fraction, acute heart failure, sepsis, or stable angina. An important fact yet to be explored is the clinical applicability of ivabradine in patients with atrial fibrillation, a concern that beckons future investigation. In this review, the concept of overlap theory it introduced, along with its application to expand the indication of ivabradine and the overlap theory-guided optimal ivabradine therapy.<\/jats:p>","DOI":"10.3390\/medicina60020303","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:47:45Z","timestamp":1707713265000},"page":"303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Implications of Ivabradine in the Contemporary Era"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"first","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Toyama 930-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","article-title":"JCS\/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"27","author":"Tsutsui","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"Mcdonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.jacc.2017.04.001","article-title":"Beta-Blockers in Heart Failure Collaborative G. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients with Heart Failure","volume":"69","author":"Kotecha","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/CIRCHEARTFAILURE.115.002285","article-title":"Prognostic Significance of Resting Heart Rate and Use of beta-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients with Heart Failure and Reduced Ejection Fraction: Findings from the Swedish Heart Failure Registry","volume":"8","author":"Li","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s003950050200","article-title":"A mechanistic analysis of the force-frequency relation in non-failing and progressively failing human myocardium","volume":"93","author":"Alpert","year":"1998","journal-title":"Basic Res. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The Clinical Use of Ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study","volume":"102","author":"Bohm","year":"2013","journal-title":"Clin. Res. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/ehf2.12814","article-title":"How to consider target heart rate in patients with systolic heart failure","volume":"7","author":"Izumida","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1536\/ihj.20-788","article-title":"How to Estimate the Optimal Heart Rate in Patients with Heart Failure with Preserved Ejection Fraction","volume":"62","author":"Izumida","year":"2021","journal-title":"Int. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/1753944716669658","article-title":"Emerging role of ivabradine for rate control in atrial fibrillation","volume":"10","author":"Turley","year":"2016","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects with Chronic Heart Failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jacc.2017.03.563","article-title":"Achieving a Maximally Tolerated beta-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?","volume":"69","author":"Bhatt","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1253\/circj.CJ-12-1241","article-title":"Trend of clinical outcome and surrogate markers during titration of beta-blocker in heart failure patients with reduced ejection fraction: Relevance of achieved heart rate and beta-blocker dose","volume":"77","author":"Kato","year":"2013","journal-title":"Circ. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of Medical Therapy for Heart Failure with Reduced Ejection Fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1536\/ihj.21-387","article-title":"Implication of Ivabradine Therapy in Up-Titrating Beta-Blocker Dose in Patients with Systolic Dysfunction","volume":"62","author":"Imamura","year":"2021","journal-title":"Int. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurjhf\/hfp154","article-title":"Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: The Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)","volume":"12","author":"Swedberg","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and Safety of Ivabradine in Japanese Patients with Chronic Heart Failure\u2014J-SHIFT Study\u2014","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1152\/japplphysiol.00475.2013","article-title":"Left ventricular ejection time, not heart rate, is an independent correlate of aortic pulse wave velocity","volume":"115","author":"Salvi","year":"2013","journal-title":"J. Appl. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/apha.12704","article-title":"Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction","volume":"218","author":"Bakkehaug","year":"2016","journal-title":"Acta Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cardfail.2020.11.003","article-title":"Resting Heart Rate as an Important Predictor of Mortality and Morbidity in Ambulatory Patients with Heart Failure: A Systematic Review and Meta-Analysis","volume":"27","author":"Lau","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Writing","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcmg.2018.10.038","article-title":"Left Ventricular Diastolic Function: Understanding Pathophysiology, Diagnosis, and Prognosis with Echocardiography","volume":"13","author":"Nagueh","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.2169\/internalmedicine.7343-21","article-title":"Implications of Doppler Echocardiography-guided Heart Rate Modulation Using Ivabradine","volume":"60","author":"Hori","year":"2021","journal-title":"Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1007\/s00380-021-01864-5","article-title":"Impact of optimal heart rate on left ventricular reverse remodeling and functional improvement in patients with systolic heart failure","volume":"36","author":"Izumida","year":"2021","journal-title":"Heart Vessels"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/jocs.15394","article-title":"The implication of optimal heart rate in patients with systolic dysfunction following TAVR","volume":"36","author":"Imamura","year":"2021","journal-title":"J. Card. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.2022.16197","article-title":"Five-Year Outcomes in Patients with Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial","volume":"328","author":"Mehra","year":"2022","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/CIRCRESAHA.121.318160","article-title":"Reverse Remodeling with Left Ventricular Assist Devices","volume":"128","author":"Burkhoff","year":"2021","journal-title":"Circ. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCHEARTFAILURE.110.959684","article-title":"Reverse remodeling with left ventricular assist devices: A review of clinical, cellular, and molecular effects","volume":"4","author":"Ambardekar","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/MAT.0000000000001104","article-title":"Neurohormonal Blockade During Left Ventricular Assist Device Support","volume":"66","author":"Imamura","year":"2020","journal-title":"ASAIO J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1536\/ihj.21-468","article-title":"Implications of Heart Rate in Patients with Left Ventricular Assist Devices","volume":"63","author":"Imamura","year":"2022","journal-title":"Int. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jchf.2017.09.004","article-title":"Heart Rate in Preserved Ejection Fraction Heart Failure","volume":"5","author":"Bristow","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1536\/ihj.20-751","article-title":"Chronotropic Assessment in Patients with Constrictive Pericarditis","volume":"62","author":"Imamura","year":"2021","journal-title":"Int. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Izumida, T., Imamura, T., Nakamura, M., and Kinugawa, K. (2021). Optimal Heart Rate and Prognosis in Patients with Cardiac Amyloidosis. J. Cardiovasc. Dev. Dis., 8.","DOI":"10.3390\/jcdd8120182"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00380-022-02127-7","article-title":"Efficacy of Doppler echocardiography-guided ivabradine therapy","volume":"38","author":"Izumida","year":"2023","journal-title":"Heart Vessel"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/ehf2.14455","article-title":"Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial)","volume":"10","author":"Abdin","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/aca.aca_97_22","article-title":"Effect of Preoperative Ivabradine on Hemodynamics during Elective Off-Pump CABG","volume":"26","author":"Virmani","year":"2023","journal-title":"Ann. Card. Anaesth."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1139\/cjpp-2020-0700","article-title":"Effect of ivabradine in heart failure: A meta-analysis of heart failure patients with reduced versus preserved ejection fraction","volume":"99","author":"Hegyi","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_42","first-page":"177","article-title":"Ivabradine effects in hospitalized acute heart failure patients: A single center retrospective study","volume":"13","author":"Abdelnabi","year":"2023","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1036418","DOI":"10.3389\/fcvm.2022.1036418","article-title":"Early administration of ivabradine in patients admitted for acute decompensated heart failure","volume":"9","author":"Yang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","article-title":"Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease","volume":"26","author":"Diaz","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: A 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/ALN.0000000000003045","article-title":"Heart Rate Control during Experimental Sepsis in Mice: Comparison of Ivabradine and beta-Blockers","volume":"132","author":"Bedet","year":"2020","journal-title":"Anesthesiology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/0310057X211009913","article-title":"Effectiveness of enteral ivabradine for heart rate control in septic shock: A randomised controlled trial","volume":"49","author":"Datta","year":"2021","journal-title":"Anaesth. Intensive Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2014.04.183","article-title":"Might ivabradine be useful in permanent atrial fibrillation?","volume":"175","author":"Moubarak","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.recesp.2017.03.005","article-title":"Ivabradine as an Alternative to AV Node Ablation in a Patient with Permanent Atrial Fibrillation","volume":"70","author":"Fontenla","year":"2017","journal-title":"Rev. Esp. Cardiol. (Engl. Ed)."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10840-022-01344-4","article-title":"Ventricular rate control with ivabradine in patients with permanent atrial fibrillation","volume":"65","author":"Chan","year":"2022","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.hrthm.2023.02.012","article-title":"Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial","volume":"20","author":"Fontenla","year":"2023","journal-title":"Heart Rhythm."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:58:18Z","timestamp":1760104698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["medicina60020303"],"URL":"https:\/\/doi.org\/10.3390\/medicina60020303","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]}}}